Novel IL-1 inhibitors or combination therapies with other immunotherapies could be developed to more effectively regulate the TME and restore the anti-tumor function of the immune system by gaining a deeper understanding of the mechanisms by which IL-1 modulates the TME. This evidence concerns the gene IL1B and neoplasm.